Pregnancy after cancer: Results from a prospective cohort study of cancer survivors

Pediatric Blood and Cancer

Volumn 60, Issue 12, 2013, Pages 2001-2006

  Dillon, Katherine E ^a   Sammel, Mary D ^b   Ginsberg, Jill P ^c   Lechtenberg, Lara ^a   Prewitt, Maureen ^a   Gracia, Clarisa R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cancer survivors; Chemotherapy; Fertility; Ovarian reserve

Indexed keywords

ALKYLATING AGENT; CONTRACEPTIVE AGENT; ESTRADIOL; FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER SURVIVOR; COHORT ANALYSIS; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; INFERTILITY; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAUTERINE INSEMINATION; LEUKEMIA; LUTEINIZING HORMONE BLOOD LEVEL; LYMPHOMA; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; OVARIAN RESERVE; PREGNANCY; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCTIVE HISTORY; SARCOMA; WHOLE BODY RADIATION;

CANCER SURVIVORS; CHEMOTHERAPY; FERTILITY; OVARIAN RESERVE;

ADULT; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; FERTILITY; HUMANS; NEOPLASMS; OVARY; PREGNANCY; PREGNANCY RATE; RADIOTHERAPY; SURVIVORS;

EID: 84885773476     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24701     Document Type: Article

References (21)

1. Schover LR, Rybicki LA, Martin BA, et al. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer 1999; 86:697-709.
2. Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast 2007; 16:S175-S181.
3. American Cancer Society. Cancer treatment & survivorship facts & figures 2012-2013. American Cancer Society, Intramural Research 2012.
4. Wallace WH, Critchley HO, Anderson RA. Optimizing reproductive outcome in children and young people with cancer. J Clin Oncol 2012; 30:3-5.
5. Wallace WH. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer 2011; 117:2301-2310.
6. Gracia CR, Sammel MD, Freeman E, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012; 97:134, 40.e1.
7. Larsen EC, Muller J, Rechnitzer C, et al. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH<10IU/L. Hum Reprod 2003; 18:417-422.
8. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007; 92:3869-3874.
9. Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod 2009; 24:982-990.
10. Bath LE, Wallace WH, Shaw MP, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: Detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003; 18:2368-2374.
11. Brougham MF, Crofton PM, Johnson EJ, et al. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: A prospective study. J Clin Endocrinol Metab 2012; 97:2059-2067.
12. Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol 2009; 27:2677-2685.
13. Barton SE, Missmer SA, Berry KF, et al. Female cancer survivors are low responders and have reduced success compared with other patients undergoing assisted reproductive technologies. Fertil Steril 2012; 97:381-386.
14. van der Kaaij MA, Heutte N, Meijnders P, et al. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol 2012; 30:291-299.
15. Hamre H, Kiserud CE, Ruud E, et al. Gonadal function and parenthood 20 years after treatment for childhood lymphoma: A cross-sectional study. Pediatr Blood Cancer 2012; 59:271-277.
16. Steiner AZ, Herring AH, Kesner JS, et al. Antimullerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol 2011; 117:798-804.
17. Lie Fong S, Visser JA, Welt CK, et al. Serum anti-mullerian hormone levels in healthy females: A nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab 2012; 97:4650-4655.
18. Kelsey TW, Wright P, Nelson SM, et al. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS ONE 2011; 6:e22024.
19. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008; 93:3478-3483.
20. Freeman EW, Sammel MD, Lin H, et al. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012; 97:1673-1680.
21. Schwarz EB, Hess R, Trussell J. Contraception for cancer survivors. J Gen Intern Med 2009; 24:S401-S406.